Standardized cell sources and recommendations for good cell culture practices in genotoxicity testing.
Good cell culture practice and characterization of the cell lines used are of critical importance in in vitro genotoxicity testing. The objective of this initiative was to make continuously available stocks of the characterized isolates of the most frequently used mammalian cell lines in genotoxicity testing anywhere in the world ('IVGT' cell lines). This project was organized under the auspices of the International Life Sciences Institute (ILSI) Health and Environmental Sciences Institute (HESI) Project Committee on the Relevance and Follow-up of Positive Results in In Vitro Genetic Toxicity (IVGT) Testing. First, cell isolates were identified that are as close as possible to the isolate described in the initial publications reporting their use in genotoxicity testing. The depositors of these cell lines managed their characterization and their expansion for preparing continuously available stocks of these cells that are stored at the European Collection of Cell Cultures (ECACC, UK) and the Japanese Collection of Research Bioresources (JCRB, Japan). This publication describes how the four 'IVGT' cell lines, i.e. L5178Y TK+/-3.7.2C, TK6, CHO-WBL and CHL/IU, were prepared for deposit at the ECACC and JCRB cell banks. Recommendations for handling these cell lines and monitoring their characteristics are also described. The growth characteristics of these cell lines (growth rates and cell cycles), their identity (karyotypes and genetic status) and ranges of background frequencies of select endpoints are also reported to help in the routine practice of genotoxicity testing using these cell lines.
Servier Group, 45520, Gidy, France.
E
E
Lorge
Ramboll Environ, Little Rock, AR, 72201, USA.
M M
MM
Moore
Covance Laboratories Ltd, Harrogate, HG3 1PY, UK.
J
J
Clements
O'Donovan GT Consulting Ltd., Epperstone, Nottingham, NG14 6AG, UK.
M
M
O'Donovan
AstraZeneca, Drug Safety and Metabolism, Cambridge, CB4 0WG, UK.
M D
MD
Fellows
National Institute of Health Sciences, Tokyo, Japan.
M
M
Honma
JCRB Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
A
A
Kohara
Merck Research Laboratories, W 45-316, West Point, PA 19486, USA.
S
S
Galloway
Merck Research Laboratories, W 45-316, West Point, PA 19486, USA.
M J
MJ
Armstrong
Sanofi, 94400, Vitry sur Seine, France.
V
V
Thybaud
Exponent, Inc., 1910 St. Andrews St., Midland, MI 48640, USA.
B
B
Gollapudi
Marilyn Aardema Consulting LLC, Fairfield, OH 45014, USA.
M J
MJ
Aardema
ILSI Health and Environmental Sciences Institute, Washington, DC 20005, USA. Electronic address: jtanir@hesiglobal.org.
J Y
JY
Tanir
D000818:Animals; D016466:CHO Cells; D018929:Cell Culture Techniques / Q000592:standards*; D002478:Cells, Cultured; D003412:Cricetulus; D004249:DNA Damage / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008214:Lymphocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008223:Lymphoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D051379:Mice; D009152:Mutagenicity Tests / Q000592:standards*; D009153:Mutagens / Q000633:toxicity*; D012015:Reference Standards; D032681:Spectral Karyotyping; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism
D009153:Mutagens; D016159:Tumor Suppressor Protein p53
3.7.2C; CHL/IU; CHO-WBL; Cells; Genotoxicity; L5178Y TK(+/−); TK6